Cargando…

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer

BACKGROUND: Primary androgen deprivation therapy (PADT) is the most effective systemic therapy for patients with metastatic prostate cancer. Nevertheless, once PSA progression develops, the prognosis is serious and mortal. We sought to identify factors that predicted the prognosis in a series of pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomioka, Atsushi, Tanaka, Nobumichi, Yoshikawa, Motokiyo, Miyake, Makito, Anai, Satoshi, Chihara, Yoshitomo, Okajima, Eijiro, Hirayama, Akihide, Hirao, Yoshihiko, Fujimoto, Kiyohide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018264/ https://www.ncbi.nlm.nih.gov/pubmed/24773608 http://dx.doi.org/10.1186/1471-2490-14-33

Ejemplares similares

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy
por: Tomioka, Atsushi, et al.
Publicado: (2015)

Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid
por: Nakai, Yasushi, et al.
Publicado: (2014)

Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent Retropubic Radical Prostatectomy
por: Tanaka, Nobumichi, et al.
Publicado: (2012)

Improvement of the surgical curability of locally confined prostate cancer including non-organ-confined high-risk disease through retropubic radical prostatectomy with intentional wide resection
por: Okajima, Eijiro, et al.
Publicado: (2012)

Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA
por: Barra, Salvina, et al.
Publicado: (2014)

Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir
por: Anwar, Mekhail, et al.
Publicado: (2014)

Inhibition of COX-2 expression by topical diclofenac enhanced radiation sensitivity via enhancement of TRAIL in human prostate adenocarcinoma xenograft model
por: Inoue, Takeshi, et al.
Publicado: (2013)

Diagnostic approach for cancer cells in urine sediments by 5-aminolevulinic acid-based photodynamic detection in bladder cancer
por: Miyake, Makito, et al.
Publicado: (2014)

Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer
por: Tanaka, Nobumichi, et al.
Publicado: (2017)

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap
por: Franca, Carlos Antônio da Silva, et al.
Publicado: (2014)

The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
por: Sasaki, Takeshi, et al.
Publicado: (2018)

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus ‘X’
por: Ahmed, Kamran A, et al.
Publicado: (2014)

The optimal number of initial prostate biopsy cores in daily practice: a prospective study using the Nara Urological Research and Treatment Group nomogram
por: Tanaka, Nobumichi, et al.
Publicado: (2015)

PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure
por: Shah, T T, et al.
Publicado: (2016)

Predictive factors of (18)F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?
por: Johnson, Alison C., et al.
Publicado: (2016)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
por: Wu, Kai-Jie, et al.
Publicado: (2018)

Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer
por: Hong, Seok Young, et al.
Publicado: (2012)

The leucocyte nadir, a predictor of chemotherapy efficacy?
por: Kvinnsland, S
Publicado: (1999)

Reaching the Nadir of Medication Overuse in Chronic Migraine
por: Onan, Dilara, et al.
Publicado: (2022)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
por: Geara, Fady B., et al.
Publicado: (2017)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response
por: Kafka, Mona, et al.
Publicado: (2022)

Nadir hemoglobin is associated with poor outcome from intracerebral hemorrhage
por: Chang, Tiffany R, et al.
Publicado: (2013)

Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab
por: Shimizu, Takuto, et al.
Publicado: (2020)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Active surveillance for nonmuscle invasive bladder cancer
por: Miyake, Makito, et al.
Publicado: (2016)

Follow-up study of unilateral renal function after nephrectomy assessed by glomerular filtration rate per functional renal volume
por: Hosokawa, Yukinari, et al.
Publicado: (2014)

Association of Admission, Nadir, and Terminal Donor Creatinine With Kidney Transplantation Outcomes
por: Irish, Georgina L., et al.
Publicado: (2021)

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Absolute neutrophil count nadir in healthy pediatric patients with the Duffy-null phenotype
por: Merz, Lauren E., et al.
Publicado: (2023)

Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy
por: Tanaka, Nobumichi, et al.
Publicado: (2013)

Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method
por: Miyake, Makito, et al.
Publicado: (2021)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Low CD4 nadir linked to widespread cortical thinning in adults living with HIV
por: Hassanzadeh-Behbahani, Shiva, et al.
Publicado: (2019)

Clinical Significance of Nadir Hemoglobin in Predicting Neurologic Outcome in Infants With Abused Head Trauma
por: Lee, En-Pei, et al.
Publicado: (2020)

Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
por: Piatek, Szymon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1ech7u7pmbmdj762kl733uaaok